Claims for Patent: 8,435,752

Summary for Patent: 8,435,752

Title:	Gene polymorphisms predictive for dual TKI therapy
Abstract:	The invention provides compositions and methods for determining the likelihood of successful treatment with dual therapy such as lapatinib. The methods comprise determining the genomic polymorphism or expression level of a gene present in a predetermined region of a gene of interest and correlating the polymorphism or expression level to the predictive response. Patients identified as likely responsive are then treated with the appropriate therapy.
Inventor(s):	Lenz; Heinz-Josef (Los Angeles, CA)
Assignee:	University of Southern California (Los Angeles, CA)
Application Number:	12/523,514
Patent Claims:	1. A method for treating a human cancer patient suffering from gastric cancer, comprising administering an effective amount of lapatinib to a gastric cancer patient selected for said therapy based on possession of a genetic marker A/A for IL-8 T251A SNP, thereby treating said patient. 2. The method of claim 1, wherein the patient is suffering from advanced or metastatic gastric cancer. 3. The method of claim 1, further comprising administering an effective amount of a therapy selected from trastuzumab, capecitabine, letrozole, paclitaxel and FOLFIRI (irinotecan, 5-fluorouracil and leucovorin). 4. The method of claim 1, wherein the (A/A) for IL-8 T251A SNP is determined by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) of a tissue sample isolated from the patient. 5. The method of claim 1, wherein gene expression of IL-8 is determined by Reverse Transcriptase-Polymorphism Cain Reaction (RT-PCR). 6. The method of claim 1, wherein the patient is selected for the therapy aided by the determination that the patient is more likely responsive to the therapy than a patient lacking possession of the A/A for IL-8 T251A SNP genetic marker or more likely to experience longer overall survival than a patient lacking possession of the A/A for IL-8 T251A SNP genetic marker.

Details for Patent 8,435,752

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-01-18
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2027-01-18
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2027-01-18